相关临床试验
23
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1997
已完成
9
39.1%
尚未招募
2
8.7%
招募中
5
21.7%
终止
1
4.3%
Unknown
1
4.3%
撤回
5
21.7%
暂无批准数据
- King Hussein Cancer Center successfully manufactured 11 anti-CD19 CAR-T cell products in-house using the CliniMACS Prodigy automated closed system. - Eight patients with relapsed/refractory lymphoma were treated under a phase II trial with encouraging responses and no new safety signals. - Average vein-to-vein time was reduced to just over 15 days, demonstrating feasibility of decentralized cell therapy in a developing country. - The findings, published in JCO Global Oncology, show that point-of-care CAR-T manufacturing can expand access beyond high-income nations.
- A retrospective study confirms that ribociclib combined with endocrine therapy is effective for HR+/HER2- metastatic breast cancer in real-world settings. - The median progression-free survival (PFS) was 27.3 months, with first-line treatment showing a PFS of 32.1 months, consistent with clinical trial results. - Dose reductions due to adverse events like neutropenia and liver enzyme elevation were manageable, with no significant impact on overall survival. - The study supports the use of ribociclib in diverse patient populations, reinforcing its clinical benefit and safety profile outside controlled trial environments.
